Loading…
← CockpitCompetitor Analysis › 603939.SS Yifeng Pharmacy Chain Co Ltd Class AOpen in the cockpit ↗

Yifeng Pharmacy Chain Co Ltd Class A603939.SSCompetitor analysis, valuation and peers

China · CNY·Consumer Staples›Drugstore Chains

One of China's largest retail pharmacy chains, selling prescription and OTC medicines nationwide.

≈ A China-focused CVS/WalgreensMomentum leader 96
Mkt cap
$4.84B
US dollars, full cap
Free float
48%
of shares outstanding
$/day
$57.9M
20-day average traded
Fwd P/E
17.2×
forward earnings
ROIC−WACC
+16.3 pp
WACC 5.6%
Hurdle
-23 pp
Req g minus delivered
Next earnings
156 days
23 Apr 2027
Close · CNYCN¥26.65
1D+0.1%
1W+8.7%
1M+3.4%
3M+10.9%
6M+15.7%
YTD+22.7%
1Y+12.2%
ATR %3.6%
52w lowhigh3.7% off high

What Yifeng Pharmacy Chain does

One of China's largest retail pharmacy chains, selling prescription and OTC medicines nationwide.

Earns the retail margin on drugs bought from manufacturers and distributors, with prescription and over-the-counter sales alongside higher-margin health and beauty items, partly paid through health insurance. It grows by opening stores and acquiring smaller chains, then centralising purchasing.

In one line: A China-focused CVS/Walgreens.

Products and services

  • Retail pharmacy stores
  • Prescription/OTC drug sales

Customers

  • Retail/patient consumers

Where it sits in the supply chain

  • Consumer Staples
  • Pharmacy retail
  • Drugstore chains

What could go right

  • Pharmacy-chain consolidation
  • Aging-population drug demand

What could go wrong

  • Drug-pricing/centralized procurement policy
  • Chain price competition

Moat: narrow (scale, distribution, regulatory licence). Large multi-province pharmacy network and drug-retail licences create scale advantages over independents.

Headquarters: Nanchang, Jiangxi, China · Employees: 38,953

Named competitors

Yifeng Pharmacy Chain at a glance

Size Yifeng Pharmacy Chain (603939.SS) is a China Consumer Staples company (Drugstore Chains) with a market value of $4.84B, the 484th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥26.65 on 18 Nov 2026.

Performance Over six months the shares gained 15.7%, against +10.4% for the median peer and -20.0% for the China market (cap-weighted) — 4th highest of 10 in its peer set.

Growth Revenue grew 5.3% over the last twelve months (peer median +7.1%); the operating margin is 10.3% (peer median 4.9%).

Valuation It trades at 17.2× forward earnings against a peer median of 17.0× (5th cheapest of 9).

Price implies For today's price to make sense, revenue must grow about -9% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -23 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 16.3 points above its cost of capital (5.6% WACC).

Next results Next results expected around 23 Apr 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026603939.SS 120Peer median 116
Six months, rebased to 100: Yifeng Pharmacy Chain against the median of its 9 peers (local-currency closes).

Yifeng Pharmacy Chain financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥25.4BCN¥24.4BCN¥24.0BCN¥22.5BCN¥19.8B
Revenue growth—+2%+7%+14%—
Gross profitCN¥10.9BCN¥9.06BCN¥9.05BCN¥8.12BCN¥7.46B
EBITDAn/aCN¥4.35BCN¥4.37BCN¥3.84BCN¥3.51B
Net incomeCN¥1.82BCN¥1.68BCN¥1.53BCN¥1.41BCN¥1.26B
Free cash flowCN¥3.66BCN¥3.16BCN¥3.64BCN¥3.92BCN¥3.34B
Capital expenditureCN¥320MCN¥323MCN¥683MCN¥740MCN¥588M
Total debtCN¥9.38BCN¥11.5BCN¥13.0BCN¥10.1BCN¥8.62B

Quarterly statements and history in the cockpit →

Yifeng Pharmacy Chain competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-10%0%+10%+20%+30%0%+5%+10%+15%603233764933913088GRDN998960388331489627603939.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Yifeng Pharmacy Chain is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%20×30×603233764933913088GRDN99899627603939.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Yifeng Pharmacy Chain is the large dot.

Capital: growth delivered against growth the price implies

-10%0%+10%-10%0%10%603233764933913088GRDN998960388331489627603939.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Yifeng Pharmacy Chain is the large dot.

Yifeng Pharmacy Chain competitors and peer comparison

Head to head with its named competitors (603939.SS vs 603233.SS vs 603883.SS vs 605266.SS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Yifeng Pharmacy Chain 603939.SS$4.84B+16%+5%10%17.2×-9.3%
DaShenLin Pharmaceutical 603233.SS$3.64B+10%+7%8%15.9×-9.5%
LBX Pharmacy Chain Joint Stock 603883.SS$1.71B+13%+3%5%16.1×-10.7%
JZJ Chain Drugstore Corporation 605266.SS$293M-35%-5%0%6.2×-9.9%
Yixintang Pharmaceutical 002727.SZ$1.16B+4%-2%3%16.6×-16.0%

How Yifeng Pharmacy Chain compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Yifeng Pharmacy Chain against its 9 peers (data as of 18 Nov 2026)
Measure603939.SSPeer medianRank in peer set
1-month return+3.4%+11.2%3rd lowest of 10
6-month return+15.7%+10.4%4th highest of 10
Distance from 52-week high-3.7%-7.0%2nd highest of 10
Revenue growth (TTM)+5.3%+7.1%4th lowest of 10
Operating margin10.3%4.9%highest of 10
Forward P/E17.2×17.0×5th cheapest of 9
Growth the price implies (Req g, 7 yrs)-9.3%-7.3%4th least demanding of 10
Growth delivered (Del g)+13.2%+10.9%5th highest of 10
Hurdle (Req g minus delivered)-22.6 pp-19.9 pp3rd least demanding of 10
ROIC minus cost of capital+16.3 pp+7.1 pp2nd highest of 10

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Yifeng Pharmacy Chain 603939.SSChina$4.84B+16%+5%10%17.2×-9.3%+13.2%
DaShenLin Pharmaceutical 603233.SSChina$3.64B+10%+7%8%15.9×-9.5%+13.6%
Sugi 7649.TJapan$3.46B-9%+9%5%17.9×-9.0%+10.9%
TSURUHA 3391.TJapan$7.15B+17%+114%4%23.8×-1.5%+9.6%
MatsukiyoCocokara & 3088.TJapan$7.51B+29%+6%8%19.5×-4.8%+15.5%
Guardian Pharmacy Services GRDNUnited States$3.09B+30%+5%6%33.3×4.4%+16.8%
Sundrug 9989.TJapan$3.07B+10%+4%6%14.9×-7.3%+5.8%
LBX Pharmacy Chain Joint Stock 603883.SSChina$1.71B+13%+3%5%16.1×-10.7%+9.7%
Create SD 3148.TJapan$1.32B+3%+9%5%n/a-11.5%+8.0%
Ain 9627.TJapan$1.25B+2%+42%4%13.8×-6.5%+16.9%

Questions

Who are Yifeng Pharmacy Chain's main competitors?
Named competitors: DaShenLin Pharmaceutical Group (603233.SS), LBX Pharmacy Chain (603883.SS), Jian Zhijia Pharmacy Chain (605266.SS), Yixintang Pharmaceutical Group (002727.SZ). The cockpit's measured peer set (industry) also includes DaShenLin Pharmaceutical (603233.SS), Sugi (7649.T), TSURUHA (3391.T), MatsukiyoCocokara & (3088.T), Guardian Pharmacy Services (GRDN), Sundrug (9989.T).
Is Yifeng Pharmacy Chain expensive compared with its peers?
On forward p/e it trades at 17.2× against a peer median of 17.0×, 5th cheapest of 9 in its peer set. For today's price to make sense, revenue must grow about -9% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -23 pp: the price already allows for a slowdown.
How has Yifeng Pharmacy Chain stock performed?
Over six months to 18 Nov 2026 the shares returned +15.7% against +10.4% for the median peer; over one year +12.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.